



(11)

EP 3 271 389 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

**Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73**

(51) Int Cl.:

C07K 16/10^(2006.01) A61P 31/18^(2006.01)

(86) International application number:

PCT/US2016/023145

(48) Corrigendum issued on:

22.04.2020 Bulletin 2020/17

(87) International publication number:

WO 2016/154003 (29.09.2016 Gazette 2016/39)

(45) Date of publication and mention
of the grant of the patent:

12.02.2020 Bulletin 2020/07

(21) Application number: **16716979.6**

(22) Date of filing: **18.03.2016**

(54) **NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE**

NEUTRALISIERENDE ANTIKÖRPER GEGEN GP120 UND DEREN VERWENDUNG

ANTICORPS NEUTRALISANTS DIRIGÉS CONTRE GP120 ET UTILISATION DE CEUX-CI

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **20.03.2015 US 201562136228 P
03.11.2015 US 201562250378 P**

(43) Date of publication of application:

24.01.2018 Bulletin 2018/04

(60) Divisional application:

20156388.9

(73) Proprietor: **The United States of America, as
represented by
the Secretary, Department of Health and
Human Services
Bethesda, MD 20852-7660 (US)**

(72) Inventors:

- **CONNORS, Mark
Bethesda, MD 20814 (US)**
- **HUANG, Jinghe
Bethesda, MD 20892 (US)**
- **KANG, Byong, Ha
Bethesda, MD 20814 (US)**

- **MASCOLA, John
Bethesda, MD 20892 (US)**
- **ISHIDA, Elise
Bethesda, MD 20892 (US)**
- **ZHOU, Tongqing
Bethesda, MD 20892 (US)**
- **KWONG, Peter
Bethesda, MD 20892 (US)**
- **ZHENG, Anqi
Bethesda, MD 20892 (US)**

(74) Representative: **Gowshall, Jonathan Vallance
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München (DE)**

(56) References cited:

WO-A1-2012/154312 WO-A1-2013/163427

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 271 389 B8

- | | |
|--|---|
| <ul style="list-style-type: none">• XUELING WU ET AL: "Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 329, no. 5993, 13 August 2010 (2010-08-13), pages 856-861, XP002669441, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1187659 [retrieved on 2010-07-08] | <ul style="list-style-type: none">• MCKAY BROWN ET AL: "Tolerance to single, but not multiple, amino acid replacements in antibody V-H CDR2: A means of minimizing B cell wastage from somatic hypermutation?", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 156, no. 9, 1 January 1996 (1996-01-01), pages 3285-3291, XP002649029, ISSN: 0022-1767 |
|--|---|